Provided herein are devices and methods for topically and controllably delivering cargo across or into biological tissues, particularly the skin. These devices permit delivery of cargo to deeper cell layers of a tissue. These devices include microstructure arrays comprising nanochannels. Also disclosed is a device comprising a one or more microstructure arrays encased in a frame.

A device includes a basal portion and a plurality of blade portions disposed on the basal portion. The blade portion has a thin shape, and a distal end portion of the blade portion has a convex shape.

A medical device for delivering a drug compound through a stratum corneum includes a support having an aperture, an array of microneedles extending outwardly from the support, a plurality of nanostructures associated with each microneedle, and a reservoir wherein the drug compound is retained. At least one microneedle contains a shaft extending from the support. The shaft includes a tip configured to penetrate the stratum corneum. The shaft defines a channel extending from the support to the tip. The channel is in at least partial alignment with the aperture. At least some of the microneedles of the array of microneedles each have a cross-sectional dimension of from about 1 micrometer to about 1 millimeter. At least some of the nanostructures have a cross-sectional dimension less than about 500 nanometers and greater than about 5 nanometers and an aspect ratio of from about 0.2 to about 5.

A uniformity control membrane can be securely engaged against an upstream side of a microneedle array and configured so that resistance to flow through the uniformity control membrane is substantially greater than the resistance to flow through the microneedle array. These differences in flow resistance can facilitate uniform administration of a liquid formulation into the patient's skin across a broad area and at a relatively low pressure, such as by way of capillary action. The administration of the liquid formulation into the patient's skin across the broad area can result from the liquid formulation being administered by way of at least a majority of the microneedles of the microneedle array.

Disclosed are medical devices that incorporate siRNA. In addition to one or more siRNA constructs, devices include nanostructures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Microneedles may be incorporated on devices. The pattern including nanostructures may be formed on the surface of the microneedles.

Provided herein are devices and methods for topically and controllably delivering cargo or collecting samples into or from biological tissues, particularly the skin. These devices permit delivery of cargo and collection of samples from cell layers deep within a tissue. These devices include microstructure arrays comprising nanochannels. Also disclosed is a device comprising a one or more microstructure arrays encased in a frame.

The present invention provides a method for treating a condition or disease in a subject, comprising administering to the subject's skin a composition comprising an effective amount of one or more bioactive formulations and compositions, including neurotoxins, wherein the composition is administered with a single-chamber or multi-chamber microchannel delivery device.

A medical device for delivering a drug compound through a stratum corneum includes a support having an aperture, an array of microneedles extending outwardly from the support, a plurality of nanostructures associated with each microneedle, and a reservoir wherein the drug compound is retained. At least one microneedle contains a shaft extending from the support. The shaft includes a tip configured to penetrate the stratum corneum. The shaft defines a channel extending from the support to the tip. The channel is in at least partial alignment with the aperture. At least some of the microneedles of the array of microneedles each have a cross-sectional dimension of from about 1 micrometer to about 1 millimeter. At least some of the nanostructures have a cross-sectional dimension less than about 500 nanometers and greater than about 5 nanometers and an aspect ratio of from about 0.2 to about 5.

A uniformity control membrane can be securely engaged against an upstream side of a microneedle array and configured so that resistance to flow through the uniformity control membrane is substantially greater than the resistance to flow through the microneedle array. These differences in flow resistance can facilitate uniform administration of a liquid formulation into the patient's skin across a broad area and at a relatively low pressure, such as by way of capillary action. The administration of the liquid formulation into the patient's skin across the broad area can result from the liquid formulation being administered by way of at least a majority of the microneedles of the microneedle array.

A device and method for delivery of a bioactive agent across a dermal barrier of a subject. The device including a microneedle with a channel and a plurality of nanostructures and microstructures located on the microneedle. The nanostructures and microstructures are arranged in a fractal-like pattern. A reservoir is in fluid communication with the channel and contains a composition having a viscosity of greater than about 5 centipoise and comprising a bioactive agent. The method includes penetrating a stratum corneum of the subject with the microneedle and transporting a composition through the microneedle at a rate of greater than about 0.4 mg/hr/cm2 based upon the surface area of the microneedle.